Connect your AI

Mineralys Therapeutics, Inc. MLYS Q4 2024 Annual earnings

Reported February 12, 2025 · Before market open

EPS-$0.98Beat by $0.02

EPS estimate-$1.00

Next report

Aug 11, 2026 (In 1 week)

EPS estimate-$0.57

Financials

Q4 2024

Income statement

Operating income-$51.8M-86.8%

Net income-$48.9M-101%

EPS (diluted)-$0.98-55.6%

Balance sheet

Cash & equivalents$664.0K+3.3%

Total equity$191.3M-20.7%

Total assets$205.9M-18.2%

Cash flow

Operating cash flow-$66.8M-131%

Free cash flow-$66.8M-131%

Valuation & ratios

Valuation

as of 12/31/24

Market cap$612.65M+77.7%

Returns & leverage

Return on equity-82.2%—

Current ratio14×-9.7×

Versus estimates

Diluted EPS

Q1 2026-$0.47Beat by $0.04 Q4 2025-$0.40Beat by $0.12 Q3 2025-$0.52Beat by $0.14 Q2 2025-$0.66Beat by $0.12 Q1 2025-$0.79Beat by $0.23

Q4 2024-$0.98Beat by $0.02

Ask the moment Mineralys Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did Mineralys Therapeutics, Inc. report Q4 2024 earnings?: Mineralys Therapeutics, Inc. (MLYS) reported Q4 2024 earnings on February 12, 2025 before market open.
What were Mineralys Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Mineralys Therapeutics, Inc. reported eps of $-0.98 for Q4 2024.
Did Mineralys Therapeutics, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-1.00 by $0.02.
Where can I find Mineralys Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001933414-25-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.